Antibody discovery specialist AbCellera Biologics Inc (Nasdaq:ABCL) announced on Wednesday that it has expanded its existing collaboration with pharmaceutical company Eli Lilly and Company (NYSE:LLY) to discover therapeutic antibodies for immunology, cardiovascular disease and neuroscience.
The expanded agreement builds on a successful partnership established in 2020, which included eight programmes and an exclusive licence to AbCellera's COVID-19 antibody programme.
Lilly has the right to develop and commercialise antibodies resulting from the collaboration. AbCellera will receive upfront and research payments, as well as potential milestone payments and royalties.
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children
GSK secures EU approval for fully liquid Menveo vaccine
Oxford Nanopore and UK Biobank partner to create world's largest epigenetic dataset
Novartis' Kisqali approved in EU for broader population of high-risk early breast cancer patients
Faron Pharmaceuticals reports positive interim Phase 2 BEXMAB trial results
MaxScientific signs licensing deal with Seragon Biosciences
PTC Therapeutics reports utreloxastat trial in ALS patients failed to meet efficacy endpoints
MaaT Pharma announces positive IASO trial results for MaaT033 in ALS
Palatin Technologies completes UC patient enrolment in Phase 2 PL8177 study
ReviR Therapeutics receives research grant from Kennedy's Disease Association
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
IGC Pharma reports Phase 2 data highlighting cognitive gains with IGC-AD1 for Alzheimer's treatment